First-line treatment for advanced SMARCA4-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a combination therapy (called ABCP) as the first treatment for advanced non-squamous lung cancer that has a specific genetic change called SMARCA4. The goal is to see if this treatment is safe and works well for people who have not had prior systemic therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-squamous non-small cell lung cancer that is stage IIIB, IIIC, or IV, and cannot be removed by surgery or treated with radiation.
- Your tumor must have a SMARCA4 mutation, found through a special genetic test (NGS).
- You must not have had any prior cancer treatment (like chemotherapy or immunotherapy) for this condition.
- You must not have certain gene changes (EGFR, ALK, or ROS1).
- You must be in good physical condition (ECOG 0-1) and be able to give blood samples and medical history.
- You must not have active autoimmune disease, interstitial lung disease, or a high risk of bleeding that would prevent using one of the study drugs (bevacizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This study tests a new drug called ABBV-1480 combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see if it works as well as or better than the current standard treatment, pembrolizumab (also known as Keytruda) with chemotherapy.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of a targeted drug (anlotinib) with chemotherapy for people with a specific type of lung cancer that has a genetic change called SMARCA4 deficiency. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.